

July 16, 1994

Wayne R. Sanders  
Chairman and Chief Executive Officer  
Kimberly-Clark Corporation  
World Headquarters  
P.O. Box 619100  
Dallas, Texas 75261-9100

Dear Mr. Sanders;

Thank you for the kind reception and consideration shown to me and my husband at the annual stockholder's meeting on April 21st. I hope my statement has had a positive effect.

In this regard, I enclose a report by Clifford E. Douglas, J.D., a consultant to the American Cancer Society of Washington, D.C., which I received in June as a member of the Board of Directors of the Montgomery County American Cancer Society Unit in Dayton, Ohio. This report gives me further concern for Kimberly-Clark's direction with its production of tobacco-related products. I am convinced negative publicity will stop if there is a change in direction on the part of those involved in the manufacture of these products. I am still concerned with the potential for litigation as well.

Has Kimberly-Clark been approached and questioned by the FDA regarding its manufacture of reconstituted tobacco at LTR? My expectation is that this has occurred, but whether it has or not, I ask you to consider a quick course of action which addresses Mr. Douglas' remarks on page nine of his report under the heading "A Useful Precedent". Since Kimberly-Clark through its subsidiary LTR has a manufacturing process which currently allows it to extract nicotine and reapply it, rendering it part of the problem now under investigation by the FDA; Kimberly-Clark is therefore also in a position to become a positive part of the solution. This same technology can play a significant role in gradually reducing the nicotine content in tobacco products to a level deemed non-addictive by the FDA. By offering to take this approach before it may be required, Kimberly-Clark can lead the way helping those suffering from addiction to tobacco products cease smoking. Therefore, it would seem that a decision regarding a new direction would be prudent to consider now before more negative actions take place.

Aside from ceasing the manufacture of tobacco-related products altogether, which I believe my great-great grandfather would want to be done, this step will allow Kimberly-Clark to continue employment while addressing the social, legal and health concerns of tobacco production.

My husband and I are attending the 9th World Conference on Tobacco and Health in Paris, France from October 10th to the 14th this year, arriving the morning of Friday, October, 7th. Would it be possible for us to visit LTR while in Paris, perhaps that Friday before the conference? While this may appear to be an awkward request, my concern for Kimberly-Clark is most definitely as genuine as my concern for those addicted to tobacco products. If necessary, I would be in a position to convey Kimberly-Clark's position and actions to those congregated at this conference, which would help initiate a positive flow of information and discussion. If you deem it appropriate for me to assume such a role, I am willing to do so.

I look forward to hearing from you and await your reply.

With best personal regards,

Theda Jessen  
9138 Beaconlight Court  
Dayton, Ohio 45458

Enc.: "The Tobacco Industry's Use of Nicotine as a Drug" by Clifford E. Douglas, J.D.  
Program cover: World Conference on Tobacco and Health